Pathophysiology of anthracycline cardiotoxicity

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Anthracyclines (ANTs) are effective cancer therapeutics that significantly reduce patient mortality.
• A major limitation of ANTs is dose-dependent cardiotoxicity (CTX), potentially leading to left ventricular dysfunction and heart failure.
• Despite proposed mitigation strategies, ANT-induced CTX remains a significant clinical challenge due to incompletely understood mechanisms.

Purpose of the Study:

• To highlight the critical need for better characterization of molecular and cellular mechanisms underlying ANT-induced CTX.
• To bridge the gap between experimental findings of cardiac damage and their clinical relevance.
• To emphasize the importance of identifying patients at high risk for CTX before administering ANT-based therapies.

Main Methods:

• Review of existing literature on anthracycline mechanisms and cardiotoxicity.
• Analysis of experimental studies demonstrating cardiac damage from ANTs.
• Discussion of the translation of experimental findings to clinical cardiotoxicity.

Main Results:

• Incomplete understanding of the molecular and cellular basis of ANT-induced cardiotoxicity.
• Uncertainty regarding the clinical translation of experimentally observed cardiac damage.
• Identification of genetic profiling as a promising avenue for risk stratification.

Conclusions:

• Further research is essential to elucidate the mechanisms of ANT-induced cardiotoxicity.
• Improved understanding is needed to correlate experimental findings with clinical outcomes.
• Genetic profiling holds potential for identifying patients susceptible to cardiotoxicity, enabling safer anthracycline use.